WilmerHale Steers Rare-Disease Biotech Through $75M IPO
Biopharmaceutical company Imara Inc. braved the public markets and began trading Thursday after a $75.2 million initial public offering steered by WilmerHale that priced at the low end of its expected...To view the full article, register now.
Already a subscriber? Click here to view full article